US pharmaceutical company Pfizer announced on Tuesday that it expects to bill about $ 15 billion in 2021 with its COVID-19 coronavirus vaccine developed with BioNTech, which is about 25% of your company’s forecasts..
Pfizer, which reported its quarterly and cumulative results this morning, noted that its total billing forecast is between $ 59,400 million and $ 61,400 million for the full fiscal year, a figure that reflects the progressive vaccination of countries and their economic recovery.
In 2020, the company made a profit of $ 9,616 million, 41% less than the previous year, while its revenues increased slightly by 2% to 41,908 million, mainly due to sales of oncology and internal medicine.
“Our ability to move quickly and use state-of-the-art science to help address the world’s greatest medical challenges has been challenged by the COVID-19 pandemic. Our record success in developing a vaccine, together with our partner BioNTech, is just one example of what this new Pfizer is capable of, ”said its CEO Albert Bourla.
Two months ago, the COVID-19 vaccine developed by Pfizer and BioNTech was the first in the world to be approved for emergency use by authorities in the United Kingdom, and now has a green light in more than fifty countries, but the problems have been transferred. to its distribution.
Pfizer pointed out that it had agreed to deliver 200 million doses to the US government and advanced its delivery date to “the end of May”, when it had previously spoken of July, while in the European Union cases, where agreed to provide 300 million doses, and the Covax platform, 40 million doses, did not specify the data.
The pharmaceutical company, meanwhile, reiterated that its vaccine has been shown to be highly effective against new variants of the virus in its experiments, which “do not indicate the need for a new vaccine,” but said it is “ready to respond” if they do. “It simply came to our notice then. to get rid of the immunity ”of your training.
In terms of its financial results, Pfizer has already seen an improvement in its figures in the fourth quarter of 2020, including the first sales of the $ 154 million vaccine.
Between October and December, the pharmaceutical company made profits of 594 million, reversing the losses of 337 million that it suffered in the same section in 2019., and had a turnover of 11,684 million, 12% higher than the year.
During the quarter, Pfizer completed the merger announced in 2019 between the Upjohn business and GlaxoSmithKline’s Mylan, creating a new generic drug maker called Viatris.
Throughout the year, half of sales corresponded to oncology products (almost $ 11 billion, an increase of 21%) and internal medicine (nine billion, up 2%).
The Pfizer vaccine division brought in about 6.5 billion (2% more) and the one with the highest projection was that of rare diseases, which increased by 29% to almost three billion.
Pfizer raised its earnings per share forecast in 2021 “primarily due to further improvements in COVID-19 vaccine billing prospects” to between $ 3.10 and $ 3.20, up from $ 3 to $ $ 3.10 he had announced by mid-January.
The results had a mixed reception on Wall Street and at the beginning of the session its shares fell by about 3%. In the last year, they have lost 3% of their value.
OA
